Pila Pharma (PILA) Investor Update summary

Business overview and market positioning

• Developing an oral TRPV1 antagonist for type 2 diabetes and obesity, aiming to offer an alternative to current treatments.

• Expects market fragmentation, with room for multiple modalities and targets in obesity and diabetes.

• Focus on oral drugs to address the large global patient population, estimated at over a billion people.

Clinical and development progress

• Completed several clinical trials in type 2 diabetes, establishing a strong safety profile and initial efficacy signals.

• Planning to initiate dedicated obesity studies, starting with rat models and progressing to human trials if successful.

• Aims to generate data within six months to assess the drug's effect on body weight regulation.

Financial update and capital allocation

• Conducting a nearly fully underwritten share issue, reflecting strong investor confidence.

• New capital will fund parallel tracks: continued diabetes development and new obesity-focused studies.

• Rights issue structure includes warrants, aligning risk with study outcomes and favoring investors.